2-异氰基乙腈 | 61323-25-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-异氰基乙腈
• 英文名称: cyanomethyl isocyanide
• 英文别名: isocyanoacetonitrile；Isocyanoacetonitril (germ.)；2-Isocyanacetonitril；2-isocyanoacetonitrile
• CAS: 61323-25-9
• 化学式: C₃H₂N₂
• 分子量: 66.0623
• InChiKey: JZYMPMDJXMQKLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-异氰基乙腈 在 叔丁醇 作用下， 以 四氢呋喃 为溶剂， 以5%的产率得到
  参考文献：
  名称：

  Eine einfache und flexible Synthese von Pyrrolen ausα,β-ungesättigten Sulfonen

  摘要：

  The addition of alkyl isocyanoacetates and isocyanoacetonitrile to alpha,beta-unsaturated sulfones affords a convenient and broad access to pyrroles with unusual substitution patterns (see Scheme 2). The alpha,beta-unsaturated sulfones required as starting materials are easily obtained from different olefines.

  DOI：

  10.1002/(sici)1522-2675(19981111)81:11<1978::aid-hlca1978>3.0.co;2-t
• 作为产物：
  描述：

  N-(氰基甲基)甲酰胺 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 2-异氰基乙腈
  参考文献：
  名称：

  制备2-氰基吡咯和合成胆色素原的新方法

  摘要：

  使用DBU在THF中将α-乙酰氧基硝基化合物4a-f与异氰基乙腈（5）缩合，以良好的产率得到2-氰基-3,4-取代的吡咯6a-f。卟啉胆碱原（PBG，12）是制备四吡咯天然产物的关键组成部分，它是由2-氰基3,4-取代的吡咯6f分四个步骤合成的。

  DOI：

  10.1016/0040-4020(96)00941-6

文献信息

• Synthesis of [3-¹³C]-, [4-¹³C]- and [11-¹³C]-porphobilinogen
  作者：Prativa B. S. Dawadi、Els A. M. Schulten、Johan Lugtenburg

  DOI：10.1002/jlcr.1602

  日期：2009.7

  [4-13C]-porphobilinogen 1a, [3-13C]-porphobilinogen 1b and [11-13C]-porphobilinogen 1c are prepared from [1-13C]-3-(tetrahydropyran-2′-yloxy)-propionaldehyde 2a, methyl [4-13C]-4-nitrobutyrate 3b and [1-13C]-isocyanoacetonitrile 5c, respectively. The building blocks 2, 3 and 5 can be prepared efficiently in any isotopomeric form. Via base-catalyzed condensation of these building blocks porphobilinogen can be enriched with 13C and 15N stable isotopes at any position and combination of positions. Copyright © 2009 John Wiley & Sons, Ltd.

  来自[1-13C]-3-(四氢吡喃-2'-基氧)-丙醛2a、甲基[4-13C]-4-硝基丁酸酯3b和[1-13C]-异氰基乙腈5c，分别合成了[4-13C]-卟胆原1a、[3-13C]-卟胆原1b和[11-13C]-卟胆原1c。构件2、3和5可以在任何同位素形式下高效制备。通过这些构件的碱催化缩合反应，可以在任何或组合的位置上丰富卟胆原的13C和15N稳定同位素。版权所有 © 2009 John Wiley & Sons, Ltd.
• Immobilization of cerium (IV) and erbium (III) in mesoporous MCM‐41: Two novel and highly active heterogeneous catalysts for the synthesis of 5‐substituted tetrazoles, and chemo‐ and homoselective oxidation of sulfides
  作者：Somayeh Molaei、Mohammad Ghadermazi

  DOI：10.1002/aoc.4854

  日期：2019.7

  well‐ordered 2D‐hexagonal cerium (IV) and erbium (III) embedded functionalized mesoporous MCM‐41(MCM‐41@Serine/Ce and MCM‐41@Serine/Er) have been developed via functionalization of mesoporous MCM‐41. The surface modification method has been used in the preparation of serine‐grafted MCM‐41 and led to the development of MCM‐41@Serine. The reaction of MCM‐41@Serine with Ce (NH4)2(NO3)6·2H2O or ErCl3·6H2O in ethanol

  两个秩序井然2D -六角形铈（IV）和铒（III）嵌入官能介孔MCM - 41（MCM-41 @丝氨酸/ Ce和MCM - 41 @丝氨酸/ Er）的已通过孔MCM的官能化开发的- 41。表面修饰方法已用于制备丝氨酸移植的MCM - 41，并导致了MCM-41 @ Serine的发展。MCM-41 @ Serine与Ce（NH 4）2（NO 3）6 ·2H 2 O或ErCl 3 ·6H 2的反应乙醇在回流下的O导致MCM-41 @ Serine / Ce和MCM-41 @ Serine / Er催化剂的组织。这些催化剂的结构是通过扫描电子显微镜，作图，能量色散X射线光谱，傅立叶变换红外，热重分析，X射线衍射，电感耦合等离子体和Brunauer-Emmett-Teller分析确定的。这些MCM-41 @ Serine / Ce和MCM-41 @ Serine / Er催化剂在硫化物氧化和5-
• Oligosubstituted Pyrroles Directly from Substituted Methyl Isocyanides and Acetylenes
  作者：Alexander V. Lygin、Oleg V. Larionov、Vadim S. Korotkov、Armin de Meijere

  DOI：10.1002/chem.200801395

  日期：2009.1

  methyl isocyanides 1 onto the triple bond of electron‐deficient acetylenes 2 represents a direct and convenient approach to oligosubstituted pyrroles 3. The scope and limitations of this reaction (24 examples, 25–97 % yield) are reported along with an optimization of the reaction conditions and a rationalization of the mechanism. In addition, a related newly developed CuI‐mediated synthesis of 2,3‐disubstituted

  α-金属化甲基异氰酸酯1在缺电子乙炔2的三键上的正式环加成反应是低取代吡咯3的直接便捷方法。报道了该反应的范围和局限性（24个实例，产率为25-97％），以及对反应条件的优化和机理的合理化。此外，还描述了相关的新开发的Cu I介导的，由未活化的末端炔烃衍生的乙炔铜与取代的甲基异氰酸酯反应的2，3-二取代的吡咯的合成方法（11个实例，产率为5-88％）。
• [EN] BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT<br/>[FR] DÉRIVÉS DE BENZODIAZÉPINE, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA DÉFICIENCE COGNITIVE
  申请人：MEKONNEN BELEW

  公开号：WO2016205739A1

  公开（公告）日：2016-12-22

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于具有或有风险患上与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、雷特综合症、强迫行为和物质成瘾。
• BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：AgeneBio, Inc.

  公开号：US20180170941A1

  公开（公告）日：2018-06-21

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患有与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、瑞特综合症、强迫行为和物质成瘾。它还涉及在治疗与之相关的脑癌（包括脑肿瘤，例如髓母细胞瘤）和认知障碍的情况下，如本文所述使用α5含有的GABAA受体激动剂（例如，α5含有的GABAA受体正向变构调节剂）。